We’re excited to announce a strategic collaboration with NuvOx Therapeutics to support their Phase 2b #glioblastoma trial, funded by a grant from the National Cancer Institute (NCI). Under the award, FYR will apply its EV-Omics™ (EVO) platform and SPARCs™ enrichment technology to longitudinal blood samples collected in NuvOx’s RESTORE trial of NanO₂™, a radiosensitizer designed to reverse tumor hypoxia. The collaboration will explore extracellular-vesicle biomarkers that reflect hypoxia biology, correlate with treatment exposure, and help clinicians differentiate pseudoprogression from true progression—a persistent challenge in glioblastoma management. We’re proud to contribute to this important effort alongside NuvOx and look forward to advancing meaningful outcomes for patients impacted by glioblastoma. Read full press release here: https://lnkd.in/gW2VNnye 📌 Interested in learning more about our EV‑Omics technology or exploring how liquid biopsies can enhance your clinical trial program? Contact us at bd@fyr.bio.
Fyr Collaborates with NuvOx on Glioblastoma Trial
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development